---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Pharmacology questions"
description: "Pharmacology questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Trelegy work (mechanism of action)? Why does Trelegy include a LAMA (umeclidinium)? How long does Trelegy stay in your system (half-life)? How is Trelegy metabolized? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Pharmacology questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)  
Indication pages: [Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)

## Mechanism

<a id="trelegy-mechanism"></a>

### How does Trelegy work (mechanism of action)?

> “TRELEGY ELLIPTA contains fluticasone furoate, umeclidinium, and vilanterol. The 
> mechanisms of action described below for the individual components apply to TRELEGY 
> ELLIPTA. These drugs represent 3 different classes of medications (an ICS, an anticholinergic, 
> and a LABA), each having different effects on clinical and physiological indices.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=23)

> “Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=23)

> “Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an 
> anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the 
> airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth 
> muscle leading to bronchodilation.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=24)

> “The pharmacologic effects of beta2-adrenergic agonist drugs, including vilanterol, are at least in 
> part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the 
> conversion of adenosine triphosphate (ATP) to cyclic-3ʹ,5ʹ-adenosine monophosphate (cyclic 
> AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition 
> of release of mediators of immediate hypersensitivity from cells, especially from mast cells.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=24)

<a id="trelegy-lama-role"></a>

### Why does Trelegy include a LAMA (umeclidinium)?

> “Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic.”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=Umeclidinium%20is%20a%20long%2Dacting%20muscarinic,referred%20to%20as%20an%20anticholinergic.)

> “The mechanism of LAMA in the airways is primarily attributed to blocking acetylcholine from binding to muscarinic receptors.”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=The%20mechanism%20of%20LAMA%20in,from%20binding%20to%20muscarinic%20receptors.)

> “Because LAMA works through a distinct complementary pathway from LABA, it can help increase bronchodilation beyond what may be achieved with a single bronchodilator.<sup>12,13</sup>”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=Because%20LAMA%20works%20through%20a,be%20achieved%20with%20a%20single)

## Pharmacokinetics

<a id="trelegy-half-life"></a>

### How long does Trelegy stay in your system (half-life)?

> “Excretion: Fluticasone Furoate: The plasma elimination half-life following repeat-dose inhaled 
> administration averaged 24 hours.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 27, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=27)

> “Umeclidinium: The effective half-life after once-daily oral dosing is 11 hours.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 27, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=27)

> “Vilanterol: The effective half-life for vilanterol, as determined from inhalation 
> administration of multiple doses, is 11 hours.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 28, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=28)

<a id="trelegy-metabolism"></a>

### How is Trelegy metabolized?

> “Fluticasone furoate is cleared from systemic circulation 
> principally by hepatic metabolism via CYP3A4 to metabolites with significantly reduced 
> corticosteroid activity.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 27, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=27)

> “Umeclidinium: In vitro data showed that umeclidinium is primarily metabolized by the 
> enzyme cytochrome P450 2D6 (CYP2D6) and is a substrate for the P-glycoprotein (P-gp) 
> transporter.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 27, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=27)

> “Vilanterol: In vitro data showed that vilanterol is metabolized principally by CYP3A4 
> and is a substrate for the P-gp transporter.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 27, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=27)

<a id="trelegy-excretion"></a>

### How is Trelegy eliminated from the body?

> “Following intravenous dosing with radiolabeled fluticasone 
> furoate, mass balance showed 90% of the radiolabel in the feces and 2% in the urine.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 27, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=27)

> “Following 
> intravenous dosing with radiolabeled umeclidinium, mass balance showed 58% of the radiolabel 
> in the feces and 22% in the urine. The excretion of the drug-related material in the feces 
> following intravenous dosing indicated elimination in the bile.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 27, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=27)

> “Following oral administration of radiolabeled 
> vilanterol, mass balance showed 70% of the radiolabel in the urine and 30% in the feces.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 28, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=28)

Note: The passages concern fluticasone furoate, umeclidinium, and vilanterol, in that order.

<a id="trelegy-absorption"></a>

### How much of an inhaled Trelegy dose is absorbed?

> “Fluticasone Furoate: Following inhaled administration of fluticasone furoate, Cmax occurred 
> within 0.5 to 1 hour. Absolute bioavailability of fluticasone furoate when administered by 
> inhalation was 15.2%, primarily due to absorption of the inhaled portion of the dose delivered to 
> the lung. Oral bioavailability from the swallowed portion of the dose is low (approximately 
> 1.3%) due to extensive first-pass metabolism.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 26, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=26)

> “Umeclidinium is mostly absorbed from the lung after inhaled doses 
> with minimum contribution from oral absorption.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 26, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=26)

> “Vilanterol is mostly absorbed from the lung after inhaled doses with negligible 
> contribution from oral absorption.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 26, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=26)

## Components

<a id="trelegy-inactive-ingredients"></a>

### What are the inactive ingredients in Trelegy Ellipta?

> “TRELEGY ELLIPTA is a light grey and beige plastic inhaler containing 2 foil blister strips. 
> Each blister on one strip contains a white powder blend of micronized fluticasone furoate (100 or 
> 200 mcg) and lactose monohydrate (12.4 or 12.3 mg) and each blister on the other strip contains 
> a white powder blend of micronized umeclidinium bromide (74.2 mcg equivalent to 62.5 mcg of 
> umeclidinium), micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg of vilanterol), 
> magnesium stearate (75 mcg), and lactose monohydrate (12.3 mg). The lactose monohydrate 
> contains milk proteins.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=22)

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): All indications](https://www.evicenter.com/medical-information/trelegy-ellipta)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta/indication)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trelegy-ellipta/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/trelegy-ellipta/access-and-coverage)
